Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9512829 | 0.96 | CA1 (0.37) | CA1CA2NR1I2LMNAMAPT | |
| SCHEMBL9513087 | 0.89 | KDM4E (0.32) | — | |
| SCHEMBL1247781 | 0.86 | CA1 (0.39) | CA1CA2NR1I2LMNAMAPT | |
| SCHEMBL8441278 | 0.86 | CA1 (0.39) | CA1CA2NR1I2LMNAMAPT | |
| SCHEMBL21302457 | 0.85 | CA1 (0.33) | CA1CA2LMNAMAPT | |
| SCHEMBL8922405 | 0.85 | CA1 (0.40) | CA1CA2NR1I2LMNAMAPT | |
| SCHEMBL18987341 | 0.84 | CA1 (0.40) | CA1CA2NR1I2LMNAMAPT | |
| SCHEMBL9620532 | 0.82 | CA1 (0.42) | CA1CA2NR1I2LMNAMAPT | |
| SCHEMBL1517392 | 0.82 | MAOA (0.32) | CA1CA2 | |
| SCHEMBL30659950 | 0.82 | MAOA (0.32) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728339-B1 | COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS | AMO Ireland (IE) | 2022-07-06 | — | — | EP | claimed |
| US-11359031-B2 | Composition for ophthalmological products | Johnson & Johnson Surgical Vision, Inc. (US) | 2022-06-14 | — | — | US | claimed |
| EP-3728339-A1 | COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS | Merck Patent GmbH (DE) | 2020-10-28 | — | — | EP | claimed |
| US-20200332041-A1 | COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS | MERCK PATENT GMBH (DE) | 2020-10-22 | — | — | US | claimed |
| US-10470874-B2 | Adjustable optical elements with enhanced ultraviolet protection | RXSIGHT, INC. (US) | 2019-11-12 | — | — | US | claimed |
| EP-3502147-A1 | COMPOSITION FOR OPHTHALMOLOGICAL PRODUCTS | Merck Patent GmbH (DE) | 2019-06-26 | — | — | EP | claimed |
| EP-3173826-B1 | HYDROGEL COMPOSITION AND HYDROGEL CONTACT LENSES MADE OF THE COMPOSITION | PEGAVISION CORP (TW) | 2019-02-13 | — | — | EP | claimed |
| EP-3173826-A1 | HYDROGEL COMPOSITION AND HYDROGEL CONTACT LENSES MADE OF THE COMPOSITION | Pegavision Corporation (TW) | 2017-05-31 | — | — | EP | claimed |
| EP-1928353-B1 | NOVEL ADJUSTABLE OPTICAL ELEMENTS WITH ENHANCED ULTRAVIOLET PROTECTION | CALHOUN VISION INC (US) | 2016-10-26 | — | — | EP | claimed |
| US-20160161638-A1 | UV-BLOCKING SILICONE HYDROGEL COMPOSITION AND SILICONE HYDROGEL CONTACT LENS CONTAINING THEREOF | PEGAVISION CORPORATION (TW) | 2016-06-09 | — | — | US | claimed |
| WO-2006107899-A1 | AROMATIC-BASED POLYSILOXANE PREPOLYMERS AND OPHTHALMIC DEVICES PRODUCED THEREFROM | BAUSCH & LOMB INCORPORATED (US) | 2006-10-12 | — | — | WO | claimed |
| US-20060223964-A1 | Aromatic-based polysiloxane prepolymers and ophthalmic devices produced therefrom | BAUSCH & LOMB INCORPORATED | 2006-10-05 | — | — | US | claimed |
| EP-1664855-A1 | PROCESS FOR MANUFACTURING INTRAOCULAR LENSES WITH BLUE LIGHT ABSORPTION CHARACTERISTICS | BAUSCH & LOMB INCORPORATED (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005026787-A1 | PROCESS FOR MANUFACTURING INTRAOCULAR LENSES WITH BLUE LIGHT ABSORPTION CHARACTERISTICS | BAUSCH & LOMB INCORPORATED (US) | 2005-03-24 | — | — | WO | claimed |
| US-20050055090-A1 | Process for manufacturing intraocular lenses with blue light absorption characteristics | BAUSCH HEALTH US, LLC | 2005-03-10 | — | — | US | claimed |
| US-20020049290-A1 | High refractive index hydrogel compositions for ophthalmic implants | VANDERBILT DAVID P (US) | 2002-04-25 | — | — | US | claimed |
| US-20020037984-A1 | High refractive index hydrogel compositions for ophthalmic implants | VANDERBILT DAVID P (US) | 2002-03-28 | — | — | US | claimed |
| WO-2000034804-A1 | HIGH REFRACTIVE INDEX HYDROGEL COMPOSITIONS FOR OPHTHALMIC IMPLANTS | BAUSCH & LOMB SURGICAL, INC. (US) | 2000-06-15 | — | — | WO | claimed |
| EP-0282294-B1 | Vinylsilylalkoxy arylbenzotriazole compounds and UV absorbing compositions made therefrom | IOLAB CORP (US) | 1993-12-01 | — | — | EP | claimed |
| US-4803254-A | Vinylsilylalkoxy arylbenzotriazole compounds and UV absorbing compositions made therefrom | IOLAB CORPORATION (US) | 1989-02-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10470874-B2 | Adjustable optical elements with enhanced ultraviolet protection | UACA, ERCC4, CRYAB | CA1 1346/4885CA2 1335/4885NR1I2 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.